Innovative Technology Kodikaz Therapeutic Solutions has developed the Zip-Code™ platform, a unique cell-specific gene delivery system derived from endogenous human mechanisms. This innovative approach avoids traditional viral vector challenges, making it highly attractive for biotech firms looking for safer, more effective gene therapy delivery methods.

Growing Market Focus With a mission to transform cancer treatment through targeted and durable therapies, Kodikaz is positioned at the forefront of precision oncology, appealing to organizations interested in cutting-edge, personalized treatment solutions with high societal impact.

Expanding R&D Potential Despite a small team of 2-10 employees, the company demonstrates significant scientific innovation, offering opportunities for collaboration in research, development, and technology licensing within the rapidly expanding biotech and gene therapy sectors.

Financial Trajectory Currently generating between $1M and $10M in revenue with a modest funding of $256K, Kodikaz presents a scalable investment opportunity for partners aiming to participate in pioneering gene therapy developments with potential for growth.

Strategic Collaborations Given its groundbreaking science and advanced platform, Kodikaz could benefit from partnerships with larger biotech and pharma companies for clinical development, manufacturing scale-up, and commercialization efforts, opening avenues for strategic alliances and joint ventures.